Fuse Biotherapeutics
Los Angeles, US · Founded 2021 · Delaware corporation
Founders & leadership
YW
Yuanheng Wang LiangNamed on SEC filing
JT
Jeffrey TakimotoNamed on SEC filing
BR
Brian RabinovichNamed on SEC filing
PS
Paul SongNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8.2M disclosed across 1 round · 2021
▶$8.2MraisedNov 2021 · 8 investors · PharmaceuticalsRule 506(b)
▶$8.2MraisedNov 2021 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yuanheng Wang LiangDirector
- Jeffrey TakimotoExecutive Officer
- Brian RabinovichExecutive Officer, Director
- Paul SongExecutive Officer, Director
- Offering amount
- $9.6M
- Amount sold
- $8.2M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Fuse Biotherapeutics raised?
- Fuse Biotherapeutics has disclosed $8.2M raised across 1 round.
- Where is Fuse Biotherapeutics headquartered?
- Fuse Biotherapeutics is headquartered in Los Angeles, US.